Common name
pyridin-2-amine
IUPAC name
pyridin-2-amine
SMILES
Nc1ncccc1
Common name
pyridin-2-amine
IUPAC name
pyridin-2-amine
SMILES
Nc1ncccc1
INCHI
InChI=1S/C5H6N2/c6-5-3-1-2-4-7-5/h1-4H,(H2,6,7)
FORMULA
C5H6N2
Common name
pyridin-2-amine
IUPAC name
pyridin-2-amine
Molecular weight
94.115
clogP
0.787
clogS
-0.970
Frequency
0.0031
HBond Acceptor
1
HBond Donor
2
Total PolarSurface Area
38.91
Number of Rings
1
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00654 | Tripelennamine |
|
Anti-Allergic Agents; Histamine H1 Antagonists; Histamine Antagonists; Respiratory System; Dermatologicals; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Antihistamines for Topical Use; Antihistamines for Systemic Use; Substituted Ethylene Diamines; CYP2D6 Inducers; CYP2D6 Inducers (strong); | Used for the symptomatic relief of hypersensitivity reactions, coughs, and the common cold. |
| FDBD00657 | Sulfasalazine |
|
Antirheumatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Gastrointestinal Agents; Anti-Infective Agents; Sulfonamides; Alimentary Tract and Metabolism; Aminosalicylic Acid and Similar Agents; Intestinal Antiinflammatory Agents; Antidiarrheals, Intestinal Anti-Inflammatory/antiinfective Agents; | For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent. |
| FDBD01426 | Flupirtine |
|
Analgesics; Nervous System; | Investigated for use/treatment in fibromyalgia. |
| FDBD01433 | Mepyramine |
|
Anti-Allergic Agents; Histamine H1 Antagonists; Histamine Antagonists; Respiratory System; Dermatologicals; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Antihistamines for Topical Use; Antihistamines for Systemic Use; Substituted Ethylene Diamines; Sleep Aids, Pharmaceutical; CYP2D6 Inducers; CYP2D6 Inducers (strong); | Mepyramine is a first generation antihistamine used in treating allergies, ymptomatic relief of hypersensitivity reaction, and in pruritic skin disorders. |
| FDBD01461 | Lornoxicam |
|
Anti-Inflammatory Agents, Non-Steroidal; Musculo-Skeletal System; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory and Antirheumatic Products; Oxicams; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; | For the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases. |
| FDBD01518 | Chloropyramine |
|
Histamine H1 Antagonists; Histamine Antagonists; Respiratory System; Dermatologicals; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Antihistamines for Topical Use; Antihistamines for Systemic Use; Substituted Ethylene Diamines; | For the treatment of allergic conjunctivitis, allergic rhinitis, bronchial asthma, and other atopic (allergic) conditions. |
| FDBD01545 | Crizotinib |
|
Antineoplastic Agents; Protein Kinase Inhibitors; Antineoplastic and Immunomodulating Agents; CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; | Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test. |
| FDBD01783 | Morniflumate |
|
Musculo-Skeletal System; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory and Antirheumatic Products; | |
| FDBD01792 | Talniflumate |
|
; | For the treatment of cystic fibrosis. |
9 ,
1
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 4y83_ligand_frag_0.mol2 | 4y83 | 1 | -6.52 | c1cccc(n1)N | 7 |
| 4ejn_ligand_frag_3.mol2 | 4ejn | 1 | -6.49 | c1c(nccc1)N | 7 |
| 5cep_ligand_1_2.mol2 | 5cep | 1 | -6.46 | Nc1ccccn1 | 7 |
| 4n4t_ligand_frag_3.mol2 | 4n4t | 1 | -6.45 | c1ccc(nc1)N | 7 |
| 4n4v_ligand_frag_3.mol2 | 4n4v | 1 | -6.43 | c1ccc(nc1)N | 7 |
| 2wot_ligand_1_2.mol2 | 2wot | 1 | -6.42 | Nc1ccccn1 | 7 |
| 3cth_ligand_frag_2.mol2 | 3cth | 1 | -6.42 | c1cnc(cc1)N | 7 |
| 4jnm_ligand_frag_4.mol2 | 4jnm | 1 | -6.42 | c1ccc(nc1)N | 7 |
| 2wtj_ligand_frag_4.mol2 | 2wtj | 1 | -6.41 | c1cccnc1N | 7 |
109 ,
11
